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ABSTRACT
Background: Sexually transmitted infection (STI) is a major global cause of acute illness,
infertility, long-term disability and death, with serious medical and psychological consequences to
millions people. In Ethiopia epidemiological study on STI is limited.
Objective: The aim of this study was to determine prevalence and associated risk factors of
Neisseria gonorrhoeae, Treponema palladium, Trichomonas Vaginalis and Candida species
infections.
Methods: A cross sectional study was conducted among STI patients attending Gondar town
hospitals and health centers between April and August 2013. One hundred twenty consecutive
symptomatic study participants were enrolled in the study. Socio-demographic data from each
study participant was collected using a semi-structured questionnaire. Samples (blood and
urogenital discharges) were collected and laboratory diagnosis for STI was done. Antimicrobial
susceptibility test of N. gonorrhoeae was done using disc diffusion technique. Data were
analyzed with descriptive statistics and logistic regression using SPSS version 20.
Results: The overall prevalence of laboratory confirmed STI was 89(74.1%). Candida species, T.
palladium, N. gonorrhoeae and T. vaginalis infections were accounted 39(32.5%), 36(30%),
25(20.8%) and 17(14.2%), respectively. The prevalence of Candida species and T. palladium
were higher in HIV positive patients. Unmarried patients were at higher risk of T. vaginalis
infection (AOR 5.9, 95%CI 1.18-29.9, p=0.036) as compared to married study subjects. HIV
infection (AOR 11.9, 95% CI 3.0-46.4, p=0.00) and regular alcohol intake (OR 3.9, 95% CI 1.2-
12.9, p=0.02) were also significant predictors of T. pallidum infection.  Isolated N. gonorrhea was
resistant to tetracycline (100%), penicillin (76%), ciprofloxacin (52%) and ceftriaxone (48%) and
80% of the isolates showed multidrug resistance.
Conclusions: Higher prevalence of N. gonorrhoeae, T. pallidum, T. vaginalis, and Candida
species infections among symptomatic STI suspected patients were observed. Being HIV positive
and regular alcohol intake were significant predictors of STI infections. Drug resistance of N.
gonorrhoeae to ciprofloxacin and ceftriaxone were very high. Thus, treatment of gonococcal
infection should be supported with drug susceptibility testing.
Key words: Candida species, N. gonorrhoeae, STI, sexually transmitted infection, T. pallidum T.
vaginalis
11. INTRODUCTION
Sexually transmitted infections (STIs) are group of infections or communicable diseases in
which the primary mode of transmission is through sexual contact. Some of the common STIs
include: bacterial vaginosis, herpes, Chlamydia, trichomoniasis, gonorrhea, Hepatitis B virus,
Human Immunodeficiency Virus (HIV)/ Acquired immunodeficiency syndrome (AIDS)  and
syphilis (1). STI is classified according to the type of organism causing the infection, which can
be bacterial, fungal, viral or of parasitic origin. Neisseria gonorrhoeae (N. gonorrhoeae),
Chlamydia trachomatis, Gardnerella vaginalis, Treponema palladium (T. pallidum),
Trichomonas vaginalis (T. vaginalis) are some of the most incriminated as etiological agents of
STI (2).
Neisseria gonorrhoeae, the causative agent of gonorrhea, is an intracellular human pathogen that
primarily colonizes the urogenital tract. Gonorrhea remains a global public health problem.
Nowadays worryingly, N. gonorrhoeae has developed high-level resistance to all traditional
antimicrobials used for the treatment of gonorrhea, like penicillin, tetracycline and
fluoroquinolone (3). Trichomonas vaginalis, a small, motile, flagellated, protozoan parasite,
causes trichomonal vaginitis (4). Trichomonas vaginalis is opportunistic pathogen that could
grow abnormally when the vagina ecosystem or the urethra in male has a distorted environmental
balance (2). Treponema pallidum, a thin flagellated spirochete, is the etiologic agent of syphilis.
Syphilis is typically acquired via sexual contact but the disease can also be transmitted
transplacentally and by exposure to blood or lesion exudates from infected persons in the
primary and secondary stages of the disease (5).
Sexually transmitted infections are a major global cause of acute illness, infertility, long-term
disability and death, with serious medical and psychological consequences to millions of men,
women and infants (6). Sexually transmitted infections are a major public health problem
worldwide. According to 2005 the world health organization (WHO) report, more than 448
million new cases of curable STI (Chlamydia, gonorrhea, trichomoniasis and candidiasis) and  a
total of 347 million new cases of gonorrhea, trichomoniasis and syphilis occur every year
worldwide in people aged between 15 and 49 years old. Among this majority of cases were in
developing countries. For instance, over 22% of adults with N. gonorrhoeae were found in the
2WHO African region (7). In the developing world, STI present major health, social and
economic problems, leading to considerable morbidity, mortality and stigma. The prevalence
rates apparently are far higher in developing countries where STI treatment is less accessible (8).
In sub-Saharan Africa 67% of infertility is due to STI associated tubal blockage. Post-infection
tubal damage is responsible for 30 - 40% of cases of female infertility which lead stigmatization
and divorce. In pregnant women with untreated early syphilis and gonococcal infection results
40% and 10% perinatal mortality respectively. Worldwide, 1000 - 4000 newborn babies become
blind every year because of eye infection (9). Like other developing countries, in Ethiopia, the
burden of STI is high but there is little information on the incidence and prevalence of STIs. This
is due to that people with STIs who have minor or no symptoms do not seek treatment at public
health facilities. They usually tend to take self-prescribed drugs or go to private pharmacies to
buy treatment without consulting trained health workers, lack of information on STIs, stigma
associated with attending public STI clinics, the formal public health facilities also do not report
all STI cases properly and comprehensively and economic factors  (10).
Studies indicated that some infections or co-infections of STI have the chance of increasing the
risk of HIV transmission. STIs associated with T. vaginalis, N. gonorrhoeae, T. pallidum, and C.
albicans infections enhance the acquisition and transmission of HIV (11- 13).
In resource limited countries the absence of etiologic diagnostic capacity has forced health care
providers to rely on a syndrome based approach to STI management, yet  many STIs have
common symptoms or are asymptomatic and therefore go undetected and untreated (6).
Improvement in the management of STIs can reduce the incidence of HIV infection in the
general population by about 40%. Prevention and treatment of STIs are therefore critical
components of HIV prevention and treatment strategies (9). Identifying the etiology and
prevalence of STI causing organisms is important to deliver appropriate treatment and decrease
the risk for HIV transmission. Therefore, this study primarily aimed to determine the prevalence
and associated factors of N. gonorrhoeae, T. vaginalis, T. pallidum and Candida species among
symptomatic STI suspected patients attending Gondar town hospitals and health centers.
32. LITERATURE REVIEW
Sexually transmitted infections constitute a major threat to health worldwide particularly in
developing countries in which the prevalence is much higher. STI and their complications are
amongst the top five diseases in which adults seek help in outpatient clinics (14).
A study conducted in California STI clinic among homosexual males indicated that the
prevalence of gonorrhea in different anatomic sites were 6.9% rectal, 6.0% urethral, and 9.2%
pharyngeal (15). On the other hand, a study from Colombia showed that there was 12.3%
prevalence of STI with the most frequent etiology was candidiasis (11%), N. gonorrhoeae
(1.4%) and T. vaginalis and T. pallidum (0.8% each)  (1). Moreover, the study conducted in
Marry land STI clinic to compare culture methods indicated that the prevalence of N.
gonorrhoeae was 29% of genital cultures, 3% of pharyngeal cultures, and 29% of rectal cultures
(16).
In Mongolia among female patients the prevalence of N. gonorrhoeae and T. vaginalis were 11%
and 8% respectively (17). On the other hand in Francisco gays STI clinic there were prevalence
of 0.6% for T. vaginalis and 11.4% for N. gonorrhoeae (18). Furthermore, study among men
patients indicated that the prevalence of N. gonorrhoeae and T. vaginalis were 5.1% and 2.8%
respectively. The prevalence of T. vaginalis was higher in the age groups of 30 years or older
patients. The presence of urethral discharge and nongonococcal urethritis were independent
predictors of T. vaginalis infection (19).
A study conducted in India, to determine prevalence of gonorrhea & its co-infection with other
ulcerative, non-ulcerative STI & HIV infection shows there was 14.4% prevalence of gonorrhea.
Gonorrhoeae was the most common co-infection with syphilis (6.3%) followed by C. albicans
(2.5%) and HIV (2.2%). The prevalence of syphilis among ulcerative STI patients was 36.9%
while 1.8% T. vaginalis infection was observed among non-ulcerative STI patient (20).
According to 1999 WHO estimate sub-Saharan Africa was the second to have largest number of
new infections of curable STI which accounts 69 million new cases. But, the highest rate of new
cases per 1000 population has occurred in sub-Saharan Africa (3). In Nigeria, the prevalence of
STI was 55% of which the prevalence of C. albicans and T. vaginalis were 1.5% and 27%
respectively. Age, sex and marital status were significantly associated with STI (21). Moreover,
4patients who had more than one sexual partner in the past 3 months, having a history of a
bacterial STI, being black Caribbean ethnicity, and living in a deprived area were significant
predictors of STI (22). Beside this, another study in Nigeria indicated that the prevalence of N.
gonorrhoeae was 25% and none of the study participants were infected with T. vaginalis (23).
Apart from being serious health, social and economic problems, STIs predispose to HIV
infection (24). The presence of an untreated STI can increase the risk of both acquisition and
transmission of HIV by a factor of up to 10 (7). Study conducted on HIV infected women,
Washington, indicated that there were prevalence of 11%, 6% and 4% of N. gonorrhoeae,
syphilis and T. vaginalis respectively (25). A comparative study on the prevalence of STI
pathogens in HIV infected and non-infected women from Nigeria indicated that higher
prevalence of C. albicans (77%) and T. vaginalis (12%) among HIV-positive patients were
observed as compared to the prevalence of C. albicans (20%) and T. vaginalis (2%) in HIV-
negative patients (2).
Another study indicates that there was an association of N. gonorrhoeae, cervicovaginal ulcer
disease and cervical mucopus with cervicovaginal viral shedding of HIV-1 (26). After treatment
shedding HIV-1 viral ribonucleic acid from the genital tract was reduced from 42% to 21% (26,
27).
According to WHO estimate from HIV sentinel surveillance among women attending antenatal
care clinics and commercial sex workers on selected sites in Ethiopia, the prevalence of T.
pallidum was 2.3% in antenatal care clinic attendees and 35% in commercial sex workers (28). A
study from Addis Ababa showed that the prevalence of N. gonorrhoeae among youth was 2.9%
(29).
Different litteraturs indicated about the emergence of drug resistance of N. gonorrhoeae for most
of the available drugs. A study from Bangladesh showed that 66% of N. gonorrhoeae isolates
were resistant to penicillin, 60.6% to tetracycline, 11.7% resistant and 26.6% intermediate
resistant to ciprofloxacin and 1% was resistant to ceftriaxone (8).
53. SIGNIFICANCE OF THE STUDY
Sexually transmitted disease causes 10-40% of prenatal mortality in infants and labor
complications for mothers and severity is higher in developing countries (9). On the other hand,
most of STI management is syndrome approach. Recent evidence from a prospective study of
women with symptomatic STIs in Ethiopia showed that genital ulcer disease was significantly
associated with treatment failure using syndromatic management (30).
Studies on prevalence and associated risk factors of T. vaginalis, N. gonorrhoeae T. pallidum
and Candida species infections among symptomatic STI patients are generally very limited in
Ethiopia in particular Gondar.
Hence, assessing the prevalence and risk factors of T. vaginalis, N. gonorrhoeae, T. pallidum,
and Candida species among symptomatic STI patients will provide information for clinicians for
appropriate management of STI patients. Moreover, policy makers and health professionals can
use the findings to design STI related programs.
64. OBJECTIVES
4.1  General objective:
 To assess the prevalence and associated risk factors of N. gonorrhoeae, T. pallidum, T.
vaginalis and Candida species infections among symptomatic STI suspected patients
attending Gondar town hospitals and health centers from April 1 to August 30, 2013.
4.2  Specific objectives
 To determine prevalence of T. pallidum, T. vaginalis, N. gonorrhoeae, Candida species
infections
 To identify the possible associated risk factors of identified infections.
 To determine antimicrobial susceptibility patterns of N. gonorrhoeae isolates.
75. MATERIALS AND METHODS
5.1. Study area
The study was conducted in Gondar town hospitals and health centers, Northwest Ethiopia. The
Town is 725 km far from Addis Ababa, located in the North Gondar Zone of the Amhara
Region. Gondar town is found north of Lake Tana on the Lesser Angereb River and Southwest
of the Simien Mountains. The town has a latitude and longitude of 12°36′N 37°28′E / 12.6°N
37.467°E with an elevation of 2133 meters above sea level. Based on figures from 2007 Central
Statistical Agency of Ethiopia, Gondar town has a total population of 207,044, of whom 98,120
are men and 108,924 women. In the town there are two hospitals (1 governmental and 1 private)
and 5 health centers.
5.2. Study design and period
A Crosse -sectional study was conducted from  April 1 to August 30, 2013.
5.3. Population
5.3.1. Source population
Those STI suspected patients who have access to visit Gondar town hospitals and health centers.
5.3.2. Study Population
All STI suspected patients attending Gondar town hospitals and health centers during the study
period.
5.4. Exclusion criteria
Those patients under antibiotic treatment during 7 days before the enrolment of this study were
excluded. Female patients who were on menstruation at the time of examination were also
excluded from the study.
5.5. Variables
5.5.1. Dependent variables
 Prevalence of N. gonorrhoeae, T. pallidum and T. vaginalis and Candida species
infections.
 Antimicrobial susceptibility of N. gonorrhoeae.
85.5.2. Independent variables
 Age,
 Sex,
 Marital status,
 Educational status
 Occupation,
 Number of sexual partners,
 History of STI,
 Sexual orientation,
 Prostitute contacts,
 History of abortion,
 Condom use
 Economical status.
 risk behaviors(alcohol, cigarette, chat consumption
5.6. Sample size and sampling technique
By using convenient sampling technique, 120 consecutive consenting patients, age of 15-45, who
attended Gondar town hospitals and health centers STI clinic, with one or more of the complaints
as stated by WHO in its syndromic approach for the diagnosis of STI were included (31).
5.7. Data collection Procedure
5.7.1. Socio-demographic characteristics
After taking written informed consent from each study participant, semi-structured questionnaire
was used to collect socio-demographic and clinical data needed in this study. Data were collected
by trained nurses.
5.7.2. Sample collection
Urethral and vaginal specimen
External inspection of the genital area were made, and the characteristics of any local changes
such as; erythema, abrasions, ulceration, urethral discharge and vaginal discharge were noted
including color, amount, odor and consistency. In the absence of visible urethral discharge, the
9patient was asked to milk the urethra. A specimen of discharge was obtained at or just within the
urethral meatus for male and both cervical and vaginal fluids were taken for female. Two
cervical and one vaginal swabs were taken from females as well as  three  urethral  swabs were
taken from males; one for  Gram staining, one for wet mount examination which was examined
in the facilities and the other was  put on Amies transport media for N. gonorrhoeae culture at
the University of Gondar Hospital.
Venous blood collection
Five ml of venous blood, for detection T. pallidum and HIV was collected from the antecubital
vein of each patients into sterile tubes. The blood was allowed to retract and then centrifuged,
and the serum was obtained (32).
5.7.3. Laboratory methods
Isolation and Identification of N. gonorrhea:
Urethral swab and cervical swab specimens were inoculated onto Thayer Martin media (OXOID,
UK) plates containing vancomycin, colistin, nistatin and trimetoprim and incubated under 5-10%
CO2 enriched wet atmosphere for 24-48 hours. Observing polymorphonuclear leucocytes with
Gram-negative intracellular diplococci was a presumptive diagnosis of gonococcal infection.
Isolates were identified as N. gonorrhoeae on the basis of colony morphology, Gram staining,
oxidase test, and carbohydrate utilization test (32).
Antimicrobial susceptibility testing
Antimicrobial susceptibility test for N. gonorrhoeae to ceftriaxone 30μg, tetracycline 30μg,
ciprofloxacin 5μg, clindmycin 2μg, penicillin 10μg, cefoxitin 30μg and cefotaxime 30μg
(OXOID, UK) were carried out using disc diffusion method (modified Kirby-Bauer) on Thayer
Martin media, following the recommended standards of the Clinical and Laboratory Standards
Institutes (CLSI) (33). A 0.5 McFarland standard was used to have standardized inoculum density
for susceptibility test. Within 15 minutes after adjusting the turbidity of the inoculum suspension, a
sterile cotton swab was dipped into the adjusted suspension and squeezed on the wall of test tube.
The dried TMT surface plates were inoculated by streaking the swab over the entire sterile agar
surface. By using sterile forceps, the antimicrobial discs were placed on the lawn of bacterial
isolates. Thayer Martin media was incubated in a humid, 5-10% CO2 atmosphere for 18–22
10
hours at 36°C. After incubation, the diameter of each zone of inhibition was measured with a
ruler from the edges of the last visible colony-forming growth by positioned the ruler across the
centre of the disc. The results were recorded in millimeters and interpretation of susceptibility,
susceptible, intermediate, or resistant following the CLSI guidelines (33, 34).
Wet mount preparation and Identification of T. vaginalis:
All discharges collected from the patients were subjected for microscopic examination to detect
T. vaginalis. A suspension of the discharge with 0.3ml normal saline was prepared. One drop of
suspension was put on a clean slide, covered with a cover slip and immediately examined
microscopically under the low power (10x) and high power (40x) magnifications. Trichomonas
vaginalis was identified by its characteristics morphology and darting motility in a wet smear
(32).
Rapid immunochromatographic syphilis tests
Advanced quality one step rapid immunochromatographic syphilis tests (TPHA) (InTec
PRODUCTS, INC., china) having T. pallidum recombinant antigens and provide results similar
to those of specific treponemal tests was used. This was performed by adding 3 drop of serum
sample to the sample well. Test results were read after 15 minutes. A positive test was shown by
a pink-mauve line in both the control and test areas. A negative test was shown by a pink line in
the control area only. The sensitivity and specificity of the test were 85–98% and 93–98%
respectively (32).
Identification of Candida species
Candidiasis was identified in the bases of detecting yeast cells and pseudohyphae in wet
vaginal/urethral preparations and large Gram positive yeast cells and pseudohyphae in Gram
stained smears (32).
HIV-test
The presence of HIV-1/2 antibodies in the serum was determined using rapid HIV-1/2 diagnostic
test kits according to the manufacturer's instructions. The results was then interpreted following
the current national algorithm for screening of sera for HIV-1/2  infection that was adopted from
WHO. In brief, the sera were first tested with KHB (Chimbo, china) HIV-1/2. If the result was
negative it was taken as negative. For KHB positive results, further tests with STATPACK
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(Trinity biotech PLC, Ireland) HIV-1/2 were done. If the result of STAT PACK was found
positive, then the serum was considered as positive  for HIV-1/2 antibodies, if not it was tested
for a third time with a tiebreaker UNI-GOLD (MEDFOM, New York) (35).
5.8. Data quality control
The questionnair was pre-tested on 15 outpatient department patients for comprehensiveness,
effectiveness, reliability and validity. Training was given for data collectors on data collection
procedures by support of investigator, venereologist and gynecologist. Culture media sterility
was checked by incubating 5% of each batch of the prepared media at 37oc for 24 hours (33, 34).
Performance of prepared media was also checked by inoculating with control strains of N.
gonorrhea ATCC 49226.
5.9. Data analysis
Data were entered and analyzed using SPSS version 20. Descriptive statistics was applied to
determine the distribution of the socio-demographic and clinical characteristics. Bivariate
analysis was performed to examine possible risk factors for N. gonorrhoeae, T. vaginalis, T.
pallidum and Candida species infections. To obtain adjusted estimates of the odds ratio while
accounting for all confounding variables, multiple logistic regression was used. P-values < 0.05
were considered statistically significant.
5.10. Ethical considerations
The proposed study was approved by the research and ethics committee of the School of
Biomedical and Laboratory Sciences of the University of Gondar. Official permission was
obtained from each health facilities. The aim and details of the study was explained to each study
participant before obtaining their written consent for specimen collection. Confidentiality was
maintained at all levels of the study by using codes rather than names of the study participants.
Participant’s involvement in the study was on voluntary basis; participants unwilling to
participate in the study & those who wish to quit their participation at any stage were informed to
do so without any restriction. The results of all positive individuals were reported to the
respective health facilities for better management of the patients.
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6. RESULTS
6.1. Socio-demographic characteristics
A total of 120 symptomatic STI patients were enrolled in the study, of which 99 (82.5%) were
females. The mean age of the study participants was 27.8 years with a standard deviation of ±7.2
years. The majority of the study participants were in the age group < 30 years old (66.6%),
literate (61.7%) and married (48.3%). Only 32 (26.6%) patients were employed. In terms of
economical status, 37 (30.8 %) participants reported as they didn’t have their own income (Table
1). All the patients come to the health facilities without their partners.
Table 1: Socio-demographic characteristics of symptomatic STI patients attending Gondar town
hospitals and health centers from April 1 to August 30, 2013.
Variable Frequency Percentage
Sex
Male 21 17.5
Female 99 82.5
Age
15-29 80 66.7
30-45 40 33.3
Marital status
Single 49 40.8
Married 58 48.3
Widowed 2 1.7
Divorced 11 9.2
Educational status
Illiterate 46 38.3
Literate 74 61.7
Occupation
No 23 19.2
House wife 26 21.7
Sex worker 11 9.2
Student 9 7.5
Employed 42 35
Farmer 7 5.8
Other 2 1.6
Monthly income No 37 30.8
< 1200 49 40.8
>1200 34 28.4
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6.2. Prevalence of laboratory confirmed STI agents
The overall prevalence of laboratory confirmed STIs pathogens among suspected attendees of
Gondar town hospitals and health centers was 89 (74.1%). The predominant infection was due to
Candida species 39(32.5%), followed by T. pallidum 36(30%), N. gonorrhoeae 25(20.8%), T.
vaginalis 17(14.2%). Among 36 TPHA positive cases, 8 had RPR confirmed active syphilis.
Seventeen (14.2%) of the study participants were HIV positive. Majority of N. gonorrhoeae, T.
pallidum, T. vaginalis, and Candida species infections were higher on aged between 15-29 years
(Table 2).
Majority of the respondents (68.3%) had multiple sexual partners. The multiple sexual partners
among male and female patients were 90.4% and 64.6%, respectively. From the total patients, 67
(55.8%) had history of STI and 69(57.5%) had never used condom (Table 2).
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Table 2: Prevalence of laboratory confirmed STI agents among symptomatic STI suspected
patients attending Gondar town hospitals and health centers from April 1 to August 30,
2013.
Characteristics Total
no (%)
N. gonorrhea
no (%)
T. vaginalis
no (%)
T. pallidum***
no (%)
Candida
species
no (%)
Sex
Male 21(17.5) 6 (28.6) 0(0) 10(47.6) 0(0)
Female 99(82.5) 19(19.2) 17(17.2) 26(26.3) 39(39.4)
Age
15-29 80(66.7) 17(21.3) 13(16.3) 25(31.2) 28(35)
30-45 40(33,3) 8(20) 4(10) 11(27.5) 11(27.5)
Marital status
Single 62(51.7) 14(22.5) 12(19.3) 16(25.8) 20(32.3)
Married 58(48.3) 11(18.9) 5(8.6) 20(34.5) 19(32.7)
Educational status
Illiterate 46(38.3) 9(19.6) 4(8.7) 17(36.9) 13(28.3)
Literate 74(61.7) 16(21.6) 13(17.5) 19(25.6) 26(35.1)
Occupation
Employed 42(35) 11(26.1) 2(4.7) 16(38) 9(21.4)
House wife 26(21.7) 3(12) 5(29.4) 7(19.4) 9(23)
CSW 11(9.2) 2(8) 1(5.8) 6(16.6) 6(15.3)
No 23(19.2) 5(20) 3(17.6) 4(11.1) 9(23)
Others 18(15.1) 4(16) 6(33.3) 3(18.7) 6(33.3)
Income
No 37(30.8) 7(18.9) 7(18.9) 7(18.9) 11(29.7)
<1200 49(40.8) 10(20.4) 8(16.3) 15(30.6) 12(24)
>1200 34(28.4) 8(23.5) 2(5.8) 14(41.2) 16(47.1)
Condom use
Never 69(57.5) 13(18.8) 11(15.9) 19(27.5) 22(31.8)
Sometimes/Rarely 38(32 ) 9(23.3) 5(13.2) 9(23.7) 11(28.8)
Always 13(10.5) 3(23.1) 1(7.7 ) 8(61.5) 6(46.2)
HIV status
Positive 17(14.2) 1(5.8) 2(11.7) 11(64.7) 6(35.3)
Negative 103(86) 24(23.3) 15(14.5) 25(24.3) 33(32)
Had a history of
Abortion* 44(44.5) 7(15.9) 9(20.5) 16(36.4) 19(43.1)
Chew chat 18(15.0) 4(22.2) 3(16.7) 8(44.4) 4(22.2)
Drink alcohol always 26 (2.7) 8(30.8) 3(11.5) 12(46.2) 6(23.1)
Smoking 9(7.5) 3(33.3) 0(0) 5(55.5) 1(11.1)
>1 sexual partner 82(68.4) 18(21.9) 10(12.2) 27(32.9) 23(28)
New sexual contact** 42(35) 9(21.4) 4(9.5) 15(35.7) 15(35.7)
Prostitute contact+ 5(23.9) 3(60) 0(0) 2(40) 0(0)
STI 67(55.5) 16(23.9) 11(16.4) 20(29.8) 22(32.8)
Share materials 39(32.5) 6(15.3) 8(20.5) 12(30.7) 14(35.9)
Overall 120 (100) 25 (20.8) 17 (14.2) 36 (30.0) 39 (32.5)
History of abortion*= females, Prostitute contact+ = males, **-last three months, ***TPHA
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6.3. Prevalence of co-infections
Of the total patients, 24 (20%) had two or more pathogens. The most frequent co-infections were
T. pallidum and Candida species 7 (29.2%), T. pallidum and N. gonorrhoeae 5 (20.8%) and T.
vaginalis and Candida. species 3 (12.5%) (Table 3). Majority of co-infections were found among
house wife's 6 (25%), governmental employed 5 (20.8%) and commercial sex worker 4 (16.6%).
Table 3: Co-infection pattern of genital pathogens among symptomatic STI suspected patients
attending Gondar town hospitals and health centers.
Co-Infection Number Frequency Percent
N. gonorrhoeae + T.  pallidum 5 20.8
N. gonorrhoeae +T. vaginalis 2 8.3
N. gonorrhoeae + Candida species 2 8.3
T.  pallidum + T. vaginalis 1 4.16
T.  pallidum + Candida species 7 29.2
T. vaginalis + Candida species 3 12.5
N. gonorrhoeae + T.  pallidum + Candida species 1 4.16
N. gonorrhoeae + T. vaginalis + Candida species 2 8.3
T.  pallidum + T. vaginalis + Candida species 1 4.16
Total 24 100
6.4. Associated risk factors for laboratory confirmed STIs
In this study significant association was observed between HIV status and STIs. In multivariate
logistic regression analysis the odds of having STI was 5.5 time higher among HIV positive
patients (AOR 5.5, 95%CI 1.06-28.7, P= 0.04) compared to HIV negative patients. However, no
statistical significant association was observed between STI and other study variables such as
age, sex, educational status, marital status, occupation, economical status, smoking, number of
sexual partner, chat chewing (Table 4).
16
Table 4: Bivariate and multivariate analysis of risk factors of STI among symptomatic STI
suspected patients attending Gondar town hospitals and health centers from April 1 to
August 30, 2013.
Characteristics STI COR (95% CI) P AOR (95% CI) P
Positive
no (%)
Negative
no (%)
Sex
Male 15(71.4) 6(28.6) 0.89(0.3-2.9) 0.82 1.1(0.41-3.2) 0.81
Female 73(73.7) 26(26.3) 1.00 1.00
Age
15-29 61(76.3) 19(23.7) 1.55(0.6-3.9) 0.30 0.13(0.48-4.0) 0.53
30-45 27(67.5) 13(32.5) 1.00 1.00
Marital status
Single 45(72.5) 17(27.5) 0.9(0.4-2.1) 0.84 1.0(0.38-2.9) 0.90
Married 43(74.1) 15(25.9) 1.00 1.00
Condom use
Never 55(79.7) 14(20.3) 2.46(0.6-10.2) 0.16 2.5(0.93-6.9) 0.06
Sometimes/Rarely 25(65.7) 13(34.3) 1.20(0.3-5.3) 1.00 0.75(0.17-3.2) 0.70
Always 8(61.5) 5(38.5) 1.00 1.00
HIV status
Positive 15(88.2) 2(11.8) 0.32(0.1-1.6) 0.23 5.5(1.06-28.7) 0.04
Negative 73(70.2) 30(29.1) 1.00 1.00
Had a history of
Chew chat (no=1) 16(88.9) 2(11.1) 0.30(0.0-1.5) 0.22 Undefined 0.99
Drink alcohol always(no*=1) 20(76.9) 6(23.1) 1.27(0.24-4.0) 0.64 1.5(0.43-5.1) 0.51
Smoking (no=1) 7(77.8) 2(22.2) 0.77(0.1-4.4) 1.00 Undefined 0.99
>1 sexual partner (no=1) 60(73.1) 22(26.9) 0.97(0.4-2.5) 0.95 1.0(0.36-2.7) 0.99
STI (no=1) 48(71.6) 19(28.4) 0.82(0.3-2.0) 0.64 0.75(0.30-1.8) 0.54
Share materials (no=1) 30(76.9) 9(25.1) 0.76(0.3-2.0) 0.54 0.99(0.37-2.6) 0.99
COR: crude odds ratio, AOR: adjusted odds ratio, HIV: human immunodeficiency virus, STI: sexual
transmitted infection,  *: rarely/sometimes, 1= reference
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Higher prevalence of gonococcal infection were observed among males (28.9%), patients with
history of multiple sexual partner (21.9%), history of STI (23.9%) and alcohol use (24.6%).
However, in logistic regression analysis no statistically significant association was observed
between the gonococcal infection and all possible associated risk factors (Table 5).
Table 5: Bivariate and multivariate analysis of risk factors of N. gonorrhea infection among
symptomatic STI suspected patients attending Gondar town hospitals and health
centers from April 1 to August 30, 2013.
Characteristics N. gonorrhea infection COR (95% CI) P AOR (95% CI) P
Positive
no (%)
Negative
no (%)
Sex
Male 6 (28.6) 15(71.4) 1.68 (0.5-5.5) 0.37 1.2(0.2-7.0) 0.97
Female 19(19.2) 80(80.8) 1.00 1.00
Age
15-29 17(21.3) 63(78.7) 1.08 (0.4-3.1) 0.87 1.4(0.4-5.0) 0.53
30-45 8(20) 32(80) 1.00 1.00
Marital status
Single 14(22.6) 48(77.4) 1.2(0.51-3) 0.62 0.42(0.1-1.3) 0.13
Married 11(18.9) 47(81.1) 1.00
Condom use
Never 18(26.1) 41(74.9) 2.41 (0.4-17.6) 0.33 3.2(0.9-11.0) 0.65
Sometimes/Rarely 5(13.5) 11(86.5) 2.50 (0.3-23.9) 0.41 0.6(0.2-11.5) 0.61
Always 2(15.4) 11(84.6) 1.00 1.00
HIV status
Positive 1(5.8) 16(94.1) 0.21(0.0-1.6) 0.12 0.21(0.2-1.8) 0.1
Negative 24(23.3) 79(76.7) 1.00 1.00
Had a history of
Chew chat (no=1) 4(22.2) 14(77.8) 1.24 (0.3-4.6) 0.75 0.2(0.0-2.9) 0.26
Drink alcohol always(no*=1) 8(30.8) 18 (69.2) 2.01 (0.7-5.9) 0.15 0.24(0.71-8.2) 0.15
Smoking (no=1) 3(33.3) 6(66.8) 2.02 (0.4-10.2) 0.39 3.6(0.2-55.0) 0.35
>1 sexual partner (no=1) 18(21.9) 64(79.1) 1.25 (0.4-3.7) 0.65 1.2(0.39-3.9) 0.71
STI (no=1) 16(23.9) 51 (76.2) 1.53 (0.6-4.2) 0.35 0.21(0.76-5.9) 0.14
Share materials (no=1) 6(15.3) 33(84.6) 0.59 (0.2-1.8) 0.31 0.54(0.7-1.6) 0.29
COR: crude odds ratio, AOR: adjusted odds ratio, HIV: human immunodeficiency virus, *:
rarely/sometimes, 1= reference
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T. vaginalis infection was higher among singles and age group of patients 15-19 years old. In
terms of marital status, multivariate logistic regression analysis indicated that single study
participants were about 6 times more likely to have T. vaginalis infection (AOR 5.9, 95%CI
1.18-29.9, p=0.036) as compared to married study subjects However, there were no significant
difference between T. vaginalis infection and other risk factors. Furthermore, all infection of T.
vaginalis was found among females (Table 6).
Table 6: Bivariate and multivariate analysis of risk factors of T. vaginalis infection among
symptomatic STI suspected patients attending Gondar town hospitals and health centers
from April 1 to August 30, 2013.
Characteristics T. vaginalis infection COR (95% CI) P AOR (95% CI) P
Positive
no (%)
Negative
no (%)
Sex
Male 0(0) 21(100) 1.00 0.04 1.00 0.99
Female 17(17.2) 82(82.8) Undefined Undefined
Age
15-29 13(16.3) 67(83.7) 1.75 (0.5-6.9) 0.35 0.86(0.19-3.9) 0.85
30-45 4(10) 36(90) 1.00 1.00
Marital status
Single 12(19.3) 50(80.7) 2.5(0.83-7.0) 0.10 5.9(1.18-29.9) 0.03
Married 5(8.6) 53(91.4) 1.00 1.00
Condom use
Never 11(15.9) 58(84.1) 2.28  (0.3-51.5) 0.68 1.0(0.28-3.8) 0.95
Sometimes/Rarely 5(13.2) 33(86.8) 1.82 (0.2-45.5) 1.00 4.9(0.4-5.7) 0.57
Always 1(7.7 ) 12(92.3) 1.00 1.00
HIV status
Positive 2(11.7) 15(88.3) 0.78 (0.1-4.2) 1.00 0.90(0.15-52) 0.91
Negative 15(14.5) 88(85.5) 1.00 1.00
Had a history of
Chew chat (no=1) 3(17.6) 15(82.4) 1.26 (0.3-5.5) 0.72 8.2(1.0-67.1) 0.04
Drink alcohol always(no*=1) 3(11.5) 23(88.5) 0.75 (0.2-3.1) 1.00 0.93(0.19-4.6) 0.93
Smoking (no=1) 0(0) 9 (100) 0.00 (0.0-3.6) 0.35 Undefined 0.99
>1 sexual partner (no=1) 10(12.2) 72(87.5) 0.62 (0.2-2.0) 0.36 0.44(0.11-4.6) 0.22
STI (no=1) 11(16.4) 56(83.6) 1.54 (0.5-5.1) 0.43 0.14(0.41-5.3) 0.54
Share materials (no=1) 8(20.5) 31(79.5) 2.06 (0.7-6.6) 0.17 1.4(0.42-4.7) 0.56
COR: crude odds ratio, AOR: adjusted odds ratio, HIV: human immunodeficiency virus, *:
rarely/sometimes, 1= reference
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The prevalence of T. pallidum infection by TPHA was 32.5%. Of the TPHA positive patients,
6.6% of the patients were confirmed as active syphilis cases by RPR. The overall prevalence of
T. pallidum infection was higher among HIV positive patients 64.7 %( 11/17) than HIV negative
24.3 %( 25/103) counterparts. In the multivariate logistic regression analysis HIV infection (OR
11.9, 95% CI 3.0-46.4, p<0.001) and regular alcohol intake (OR 3.9, 95% CI 1.2-12.9, p=0.02)
were significant predictors of T. pallidum infection.  Patients who consume alcohol in regular
base were 3 times more likely to be infected with T. pallidum than no/non-regular alcohol users
(Table 7).
Table 7:  Bivariate and multivariate analysis of risk factors of T. pallidum infection among
symptomatic STI suspected patients attending Gondar town hospitals and health
centers from April 1 to August 30, 2013.
Characteristics T. palladium infection COR (95% CI) P AOR (95% CI) P
Positive
no (%)
Negative
no (%)
Sex
Male 10(47.6) 11(52.4) 2.55 (0.9-7.5) 0.05 0.50(0.13-1.8) 0.16
Female 26(26.3) 73(73.8) 1.00 1.00
Age
15-29 25(31.2) 55(68.8) 1.20 (0.5-3.0) 0.67 2.2(0.70-7.4) 0.30
30-45 11(27.5) 29(72.5) 1.00 1.00
Marital status
Single 14(26) 48(74) 0.6(0.3-1.4) 0.30 0.42(0.1-12) 0.13
Married 20(35) 38(65) 1.00 1.00
Condom use
Never 19(27.5) 50(72.5) 0.24 (0.1-0.9) 0.02 3.0(0.97-9.2) 0.55
Sometimes/Rarely 9(23.7) 29(76.3) 0.19 (0.0-0.89) 0.02 0.65(0.1-4.3) 0.66
Always 8(61.5) 5(38.5) 1.00 1.00
HIV status
Positive 11(64.7) 6(35.3) 5.72 (1.7-19.7) 0.00 11.9(3.0-46.4) 0.00
Negative 25(24.3) 78(75.7) 1.00 1.00
Had a history of
Chew chat (no=1) 8(44.5) 10(55.5) 2.11(0.7-6.6) 0.15 0.46(0.6-3.2) 0.43
Drink alcohol always(no*=1) 12(46.1) 14(53.9) 2.50 (0.9-6.8) 0.04 3.9(1.2-12.9) 0.02
Smoking (no=1) 5(55.5) 4(44.5) 3.23 (0.7-15.6) 0.13 2.3(0.23-23) 0.46
>1 sexual partner (no=1) 27(32.9) 55(67.1) 1.58 (0.6-4.2) 0.30 1.4(0.48-4.2) 0.52
STI (no=1) 20(29.8) 47(70.2) 0.98 (0.4-2.3) 0.96 0.76(0.29-1.9 0.58
Share materials (no=1) 12(30.7) 27(69.3) 1.06 (0.4-2.6) 0.89 0.87(0.31-2.4) 0.29
COR: crude odds ratio, AOR: adjusted odds ratio, HIV: human immunodeficiency virus, *:
rarely/sometimes, 1= reference
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All the Candida species were isolated from female patients only. The prevalence of Candida
species was higher in HIV positive patients 35.3% (6/17) than HIV negative patients 32%
(33/103). However, none of the study variables were found to be significantly associated with the
prevalence of Candida species (P> 0.05) (Table 8).
Table 8: Bivariate and multivariate analysis of risk factors of Candida species infection among
symptomatic STI suspected patients attending Gondar town hospitals and health centers
from April 1 to August 30, 2013.
Characteristics Candida species infection COR (95% CI) P AOR (95% CI) P
Positive
no (%)
Negative
no (%)
Sex
Male 0(0) 21(100) 1.00 0.00 1.00 0.99
Female 39(39.4) 60(60.6) Undefined Undefined
Age
15-29 28(35) 52(65) 1.42 (0.6-3.6) 0.40 1.4(0.49-4.2) 0.49
30-45 11(27.5) 29(72.5) 1.00 1.00
Marital status
Single 20(32.5) 42(67.5) 0.97(0.45-2) 0.95 1.00 0.98
Married 19(32.7) 39(67.3) 1.00 1.0(0.36-2.8)
Condom use
Never 25(36.3) 44(63.7) 0.91 (0.2-3.6) 1.00 1.5(0.57-4.1) 0.39
Sometimes/Rarely 9(23.7) 29(76.3) 0.50 (0.1-2.3) 0.31 1.6(0.38-7.3) 0.49
Always 5(38.5) 8(61.5) 1.00 1.00
HIV status
Positive 6(35.3) 11(64.7) 1.16 (0.3-3.8) 0.79 1.6(0.45-5.7) 0.46
Negative 33(32) 70(68) 1.00 1.00
Had a history of
Chew chat (no=1) 4(22.2) 14(77.8) 0.55 (0.1-1.9) 0.31 1.1(0.19-6.4) 0.90
Drink alcohol always(no*=1) 6 (23) 20(77) 0.55 (0.2-1.7) 0.25 1.0(0.30-3.5) 0.95
Smoking (no=1) 1(11.1) 8(88.9) 0.24 (0.0-2.0) 0.27 0.77(0.44-14) 0.86
>1 sexual partner (no=1) 23(28) 69(72) 0.46 (0.2-1.1) 0.05 0.74(0.29-1.8) 0.53
STI (no=1) 22(32.8) 45(67.2) 1.04 (0.5-2.4) 0.93 0.97(0.39-2.4) 0.95
Share materials (no=1) 14(35.9) 25(64.1) 1.32 (0.6-3.2) 0.50 0.87(0.35-2.1) 0.77
COR: crude odds ratio, AOR: adjusted odds ratio, HIV: human immunodeficiency virus, *:
rarely/sometimes, 1= reference
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6.5. Antimicrobial susceptibility pattern of N. gonorrhea strains
The antimicrobial susceptibility pattern of all isolates of N. gonorrhea is shown in Table 9. All
isolated N. gonorrhea showed resistance to at least one antimicrobial agent. The susceptibility
pattern of isolates showed that there were 100% non-susceptibility to tetracycline, 76%  non
susceptibility and 24% intermediate resistant to penicillin. Of isolated N. gonorrhea, 52% were
resistant to ciprofloxacin, 48% to ceftriaxone, 44% to cefoxitin, 32% to cefotaxime and 28% to
clindmycin. Most of the isolates (80%) were shown multiple drug resistance and 11(44%) of the
isolates were non-susceptible to both ciprofloxacin and ceftriaxone.
Table 9. Antimicrobial susceptibility pattern of N. gonorrhea isolated (n=25) among
symptomatic STI suspected patients attending Gondar town hospitals and health
centers from April 1 to August 30, 2013.
Antibiotic S I R
Penicillin 0(0) 6(24) 19(76)
Tetracycline 0(0) 0(0) 25(100)
Ciprofloxacin 4(16) 8(32) 13(52)
Ceftriaxone 13(52) - 12(48)
Cefotaxime 17(68) - 7(28)
Cefoxitin 14(56) - 11(44)
Clindmycin 18(72) - 7(28)
R; resistance, I; intermediate, S; sensitive,
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7.  DISCUSSION
Data are scarce regarding the epidemiology of STIs in most countries due to various reasons
such as stigma and discrimination associated with the STI, poor attendance of STI patients at the
public health facilities and scarcity of diagnostic facilities. The situation induces many
developing countries, including Ethiopia, to corporate syndromic approach for STI diagnosis and
treatment (10).
The overall prevalence of laboratory confirmed STI excluding HIV was 74.1%. This result was
consistent with a study done almost two decades ago in Egypt (71.6%) (36). A higher prevalence
(85%) was found, in reports from Nigeria a decade ago (37). However, comparatively lower
prevalence (39%) was reported in Ibadan, Nigeria (21).  The difference in prevalence rates might
be due to the difference in geographical location and laboratory diagnostic methods used.
In this study prevalence of N. gonorrhoeae infection (20.8%) was comparable with studies from
Mozambique (22.5%) (38), Egypt (26%) (36) and Southwestern Nigeria (25%) (23). However, it
was higher than the reports from different countries such as Vientiane (0.8%) (39), Mongolia
(11%) (17), Colombia (1.4%) (1), India (6%) (20) and Nigeria (1%) (40). Moreover, in our study
the prevalence of N. gonorrhoeae infection was four fold higher than reported by Hailemariam et
al. from Hawassa, Ethiopia (5.1%) (41). This discrepancies in the prevalence of N. gonorrhoeae
might be due to socioeconomic, cultural, geographic, development of resistance for drugs used
on syndromic management, lack of differential diagnosis and poor partner tracing system
specially in our settings.
In this study the prevalence of T. pallidum infection by TPHA was 32.5%. Among this, 6.6% of
the patients were confirmed as active syphilis cases by RPR. The prevalence of active syphilis in
this study was comparable to report from India (6%) (20). This finding was higher than the
reports from Nigeria (1.5%) (39) and 0% prevalence among ANC clients, southern Ethiopia (42).
However, our finding was relatively lower as compared to 8% in rural South Africa (43) and
15% in rural Mozambique (44). This may be due to the difference in study population and
syphilis can effectively treated with single dose of bezantine penicillin. Thus the prevalence
declines with time.
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In our study, the prevalence of T. vaginalis was 14.5%. This finding was comparable with the
report from South Africa in which the prevalence of T. vaginalis among family planning service
user was 14% (43). However, it was higher than the reports from Maputo and Ibadan where the
prevalence of T. vaginalis was 2% for each (38, 40). Furthermore, lower prevalence of T.
vaginalis were reported from HIV positive and HIV negatives women attending HIV clinic
(12%) and STI clinic (2%) in Nigeria (2), and 1.5% in  Egypt (36). In the contrary, our finding
was lower than the prevalence of T. vaginalis (24.4%) among HIV-seropositive Nigerian women
(45). These differences may be due to variation in time and among study population.
In our study the prevalence of Candida species infection (32.5%) was highest as compared to the
prevalence of N. gonorrhoeae, T. pallidum and T. vaginalis infections. This prevalence of
Candida species was lower as compared to the report from Nigeria (39%) (2). However, lower
findings were reported from Colombia (11%), Nigeria (27%), Tanzania (25.5%), and Ethiopia
(16%) (1, 21, 46,47).
Risk factors associated with STI in this study was observed between positive HIV status and STI.
In a multivariate analysis the odds of having STI was 5 fold higher among HIV positives than
their counter parts. Keeping the finding reported from Nigeria (2) HIV infections was
significantly associated with STI among symptomatic patients. Moreover, the prevalence rate of
STIs was higher (44%) among age group of 15-24 years old as compared to the other age groups.
This observation had in conformity with generally observed fact that the incidence of STIs by the
number of cases treated each year is highest among 15-24 years old (48).
Although high gonococcal infection were observed among male patients (29%), clients having
multiple sexual partner (22%), patients with history of STI (23.9%) and alcohol use (24.6%),
there were no statistically significant association observed between the gonococcal infection and
all possible associated risk factors. In contrast to our finding, reports from Ibadan, Southwestern
Nigeria (21), (22) and north-west Tanzania (46) indicated that marital status, sex and HIV status
were significant predictors of N. gonorrhoeae infections.
In this study, the prevalence of T. pallidum was higher among HIV positive patients (64.7 %) as
compared to HIV negative (24.3 %) counterparts. Furthermore, logistic regression analysis
indicated that HIV infection was significant predictor of T. pallidum. This finding was consistent
24
with reports from Kenya (49) and Addis Ababa, Ethiopia (50). Regular alcohol intake also had
significant association with T. pallidum infection (OR 3.9, 95% CI 1.2-12.9, p=0.032). This is
comparable to study from Colombia (1) and among female commercial sex works Addis Ababa,
Ethiopia (51).
Keeping the report from Nigeria (21), in this study being single was significant risk factor for T.
vaginalis infection. Females had highest prevalence of T. vaginalis compared to male patients.
This finding is comparable to the study conducted in Nigeria (39). In contrast to the reports from
Nigeria (21) and Australia (52) in our study the prevalence of T. vaginalis was higher among age
group of 15 - 19 years old patients (54.4%) and prevalence decreases when age increases. This
higher prevalence of T. vaginalis infection among young age group may be due to poor
sanitation and knowledge about STI.
Generic WHO guideline recommended that countries with resource poor settings should use
syndromic approach for STI management though in recent years there has been increased
antimicrobial resistance of N. gonorrhoeae isolates in different parts of the developing countries.
Regimens for treatment of STI range from oral or injectable fluoroquinolones and
cephalosporins.
In this study High levels of resistance to tetracycline and penicillin observed have agreement
with report from Malawi (53). A comparable results of tetracycline (100%) and penicillin
(100%) resistant N. gonorrhoeae isolates among gynecological patients were reported from
Hawassa, Ethiopia (41). Similarly  high prevalence of antimicrobial resistant N. gonorrhoeae
isolates against tetracycline (92.6%) and penicillin (94.4%) were reported from northwest
Ethiopia (54).
Currently Ethiopian ministry of health recommends single dose 500mg ciprofloxacin or 1g
ceftriaxone as first drug of choices for treatment of gonorrhea (55). In this study high prevalence
drug resistant N. gonorrhoeae isolates to ciprofloxacin (52%) and ceftriaxone (48%) were
observed. Concordant findings in the prevalence rate of ciprofloxacin resistant N. gonorrhoeae
were reported from Northwest Ethiopia (40.9%) (54) and Tanzania (77%) (46).  In contrast to
our finding, study reported from Hawassa, Ethiopia, indicated that all isolated N. gonorrhoeae
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were susceptible to ceftriaxone however, 18% of the isolates were resistance to ciprofloxacin
(41). Similarly Tibebu et al reported 40.9% and 27.8% non susceptibility of N. gonorrhoeae to
ciprofloxacin and ceftriaxone respectively (54). The discrepancy in N. gonorrhoeae drug
susceptibility pattern may be the difference in use of the two drugs for the treatment of other
diseases and the time variation.
Furthermore study conducted in Bangladesh among commercial sex workers, prevalence of
ceftriaxone resistant gonococci strains were 1% (8). In this study resistance rate of N.
gonorrhoeae isolates were relatively lower against cefotaxime (28%) as compared to ceftriaxone
(48%), though it was lower as compared to study finding reported from Hawassa (41). Similar to
cefotaxime, the lower resistance rate of isolated N. gonorrhoeae (28%) to clindmycin which is
mostly prescribed drug for pelvic inflammatory disease was observed. Even though the result is
not shown, N. gonorrhoeae isolates shows high non-susceptibility for erythromycin and
doxicycline which are use as supplement treatments for uncomplicated gonorrhoeae. The higher
resistance rate N. gonorrhoeae isolates observed in this study may be due to the use of
gonococcal drugs for the treatment of other bacterial diseases, the presence of poor illegal drug
consumption, and lack of etiologic management.
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8.  LIMITATION OF THE STUDY
As the study was conducted on small number of STI suspected symptomatic patients, it may not
show the epidemiology and determinants of these STI causing pathogens in the community. All
drugs used for the treatment of gonococcal infections were not tested.
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9. CONCLUSION
Higher prevalence of N. gonorrhoeae, T. pallidum, T. vaginalis, and Candida species infections
among STI suspected patients attending Gondar town hospitals and health centers were
observed. The prevalence of Candida species and T. palladium were higher in HIV positive
patients. Unmarried patients were at higher risk of T. vaginalis infection. Being HIV positive and
regular alcohol intake were significant predictors of T. pallidum infection. Isolated N.
gonorrhoeae showed higher antimicrobial resistance to penicillin, tetracycline, ciprofloxacin and
ceftriaxone.
10. RECOMMENDATIONS
For better understanding of the epidemiology of STI causing pathogens and the association
between different patient variables and STI associated infectious diseases large scale community
based study should be considered. Emphasize on partners tracking system (partner notification or
patient-delivered partner treatment) and education about proper condom use as one of prevention
and controlling strategy of STIs. Microbiological diagnosis and susceptibility testing of
gonococcal infections should be strengthened for early detection and appropriate management of
gonorrhea. Moreover, rational use of antibiotics and continuous antimicrobial surveillance
should be practiced in order to tackle spread of drug resistance N. gonorrhea infections.
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12. ANNEXES
Annex I. English version study participant information and consent form
Consent Form for Participation in Research Work
Date: ________ Study Number: ________
Title: Prevalence and associated risk factors of Neisseria gonorrhoeae, Treponema palladium
Trichomonas vaginalis and Candida species among symptomatic STI suspected patients
attending Gondar town hospitals and health centers, Gondar, Northwest Ethiopia.
Purpose: Study to Determine and associated risk factors of Neisseria gonorrhoeae, Treponema
palladium, Trichomonas vaginalis and Candida species among patients attending Gondar town
hospitals and health centers.
Procedure to be carried out:  We kindly invite you to take part in our project that 120 clients will
participate. If you are willing to join in our project we are so happy for participate in this study
and we need you to clearly understand the aim of this study and to sign the consent form.
As agreed to take part, you will be asked some questions relevant to the study using
questionnaire. A blood sample and urethral or vaginal swab will be collected. from sample
etiology of Gonorrhea, Trichomoniasis and syphilis will be examined.
Risk associated with the study: By participating in this research project you may feel that it has
some discomfort during giving blood and vaginal/urethral swab. But this may not be too much as
you are one of the member of the community who are at risk of this public health problem.  So
your response will help as an important input to show extent of the stated problem and help to
design appropriate strategies to manage it. There is no risk in participating in this research
project.
Benefits of this study: If you are afflicted with STI, You will be treated.
Confidentiality of your information: All information gathered from the study will remain
confidential. Your participation in this study is strictly anonymous.
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Right to Refusal or Withdraw: You have the full right to refuse from participating in this
research and this will not affect you from getting any kind healthcare service. You have also the
full right to withdraw from this study at any time you wish, without losing any of your right.
Person to contact: If you have any problems or questions related to this study you can contact
telephone to Investigator
Name : Rozina Ambachew,
Telephone number   0920130978/0935706022.
email: nanieyasu@gmail.com
Informed consent form: You are invited to participate in a study on Prevalence and associated
risk factors of Neisseria gonorrhoeae, Treponema palladium, Trhicomanes Vaginalis and
Candida species among symptomatic STI patients attending Gondar town hospitals and health
centers. If you have fully understood what will be done in the course of this study and agree to
the procedure involved, please sign the consent form.
I, the undersigned, confirm that the study was explained to me in a language that I understand.
The objectives, risks and benefits of the study were clearly explained to me. I am also assured
that participation in the study is voluntary.
Signature : __________ Date : ____________
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Annex II - English version Questionnaire
Name of  health facility  __________________                           Date of Interview: ___/___/____
Name of Interviewer: ____________________
Respondent ID Number __________________                                Facility ID____________
Age  ________ (in complete years).
Sex        Male ⎕ Female ⎕
Marital status: Single ⎕ Married ⎕ Divorced ⎕ Widowed ⎕
Educational background
Illiterate ⎕ read and write only ⎕ Primary school ⎕
Secondary school ⎕ College/university ⎕.
5.   Occupation
6.  Do you drink alcohol?
Yes ⎕ No ⎕
6.1  If  yes how often do you use?
Always ⎕ Sometimes ⎕ Never ⎕
7.  Do you chew  chat?
Always ⎕ Sometimes ⎕ Never ⎕
8.  Do you smoke   cigarette and/or other smokes  ?
Always ⎕ Sometimes ⎕ Never ⎕
9.   Have you ever had Abortion ( for female)
Yes ⎕ No ⎕
9.1     if yes how many times ?
10. How many sexual partners do  you have in your life time?
Did not have ⎕ 1 ⎕ 2 ⎕ > 3 ⎕
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10.1  If yes, did you use condoms?
Always ⎕ Sometimes ⎕ Never ⎕
11. Have you ever had sex with prostitutes?
Yes ⎕ No ⎕
11.1    if yes how many times _______
11.2 did you use condoms?
Yes ⎕                                       No    ⎕
12. Have you ever been treated for any sexually transmitted disease within last 12 months?
Yes ⎕ No ⎕
17. Have you ever share any underwear, trauther,  and  toilet bottling before?
Yes ⎕ No ⎕
18.   Have you ever had a blood test for HIV
Yes ⎕ No ⎕ Don’t know ⎕
If yes, what was the result?
Positive (infected) ⎕ Negative (not infected) ⎕ Don’t know ⎕
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Annex III. Amharic version study participant information and consent form
የምርምር ተሳታፊዎችጥናትማብራሪያ ቅፅ
ቀን-------------------- መለያ ኮድ------------------------------
የተመራማሪው ስም፡- ሮዚና አምባቸው
የጥናቱ ርዕስ፡- የጨብጥ፣ የቂጥኝና የቲባጅናሊስን ስርጭትና ለስርጭታቸው አስተዋጾ የሚያደርጉ
ምክኒያቶችንማወቅ፡፡
የጥናቱ አላማና ጥቅም፡- በጎንደር ከተማ በሚገኙ ጤና ተቋማት ላይ ባሉ የአባላዘር በሽታ ህክምና
መስጫ ክፍሎች ላይ የሚመጡ ህሙማን ያለውን የአባላዘር በሽታ ስርጭት እና ለስርጭቱ አስተዋጾ
የሚያበረክቱምክኒያቶችንማወቅ እንዲሁም የጨብጥ በሽታ አሁን ለመንጠቀምባቸው
የስራው ቅደም ተከተል፡- በጥናቱ ውስጥ 120 ሰዎች ይሳተፋሉ፡፡ በዚህ ጊዜ ውስጥ ስላለወት የጾታዊ
ባህሪ እንዲሁም ስለ አባላዘር በሽታ ስሜቶች እና ምልክቶች እንጠይቅወታለን፡፡
5 ሚሊ ሊትር ደም እና የብልት ፈሳሽ ይወስድለወታል፡፡ ከተወሰደው ናሙና ላይም ቂጥኝ፣ ጨብጥና
ቫጅናሊሲ ይሰራል፡፡ ውጤቱን ካርደወን በማሳየት ይወስዳሉ፡፡ ውጤትዎሚስጥሩ የተጠበቀ ነው ፡፡
በዚህ ጥናት ውስጥ በመሳተፎዎ ሊከሰቱ የሚችሉ ስጋቶችን የምቾት መጓደሎች ለጥናቱ
በሚወሰደው ናሙናምክንያት ሊከሰት የሚችል የተለየ ችግር እና የሚያሰጋምንም አይነት ነገር የለም
፡፡ ነገር ግን ናሙናው በሚወሰድበት ጊዜ መጠነኛ የሆነ የህመም ስሜት ሊያስከትል ይችላል
ይህየህመም ስሜትምንም አይነትችግ አያመጣም፡፡
ከጥናቱ የሚገኘውጥቅም፡- ተሣታፊዎች በገፅ የላቭራቶሪውጤቱን ያገኛሉ
የሚስጥር አጠባበቅ፡- ጥናቱ ላይ የሰጡት ማንኛውም መረኛ የሚቀመጠው በሚስጥር ነው፡፡
ማንኛውም ሰው ስለሰውውጤት የሚያውቀው ነገር ስለማይኖር ስጋት አይገባዎትም፡፡
በጥናቱመሣተፍ፡- በዚህ ጥናትመሣተፍ በፍቃደኝነት የተመሰረተ ነው፡፡
የተመራማሪውኢ-ሜል nanieyasu@gmail.com ስልክ 0920130978/0935706022
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Annex IV. Amharic version Questionnaire
መጠይቅ
የጤና ድርጅቱ ስም----------------------------- መጠይቅ የተሞላበት ቀን-------------------
የጠያቂም ስም---------------------------------- የጤና ድርጅቱመለያ ቁጥር----------------
የተጠያቂውመለያ ቁጥር---------------------------
1. እድሜ-----------------/ በሙሉ ዓመት/
2. ጾታ ወንድ□ ሴት□
3. የትዳር ሁኔታ ያገባ/ች/ □ የፈታ/ች/ □ የሞተበት/የሞተባት/□
4. የትምህርት ደረጃ ሁኔታ
ያልተማረ □ መጻፍናማንበብ የሚችል □ መጀመሪያ ደረጃ ያጠናቀቀ □
ሁለተኛ ደረጃ ያጠናቀቀ □ኮሌጅ/ዩኒቨርስቲ/ የጨረሰ□
5. የስራ ሁኔታ--------------------
6. አልኮል ትጠጣለህ/ሽ/ ? አዎ □ አልጠጣም□
7. ጫትትቅማለህ? ሁልጊዜ □ አንዳንድ ጊዜ □ አልቅምም□
8. ሲጋራ ወይም ሌላ የሚጨሱ ነገሮችን ታጨሣለህ/ሽ/? ሁልጊዜ □ አንዳንድ ጊዜ□
አላጨስም□
9. ለሴቶች ብቻ
9.1 ውርጃ ፈፅመሽ ታውቂያለሽ? አዎ □ አላውቅም□
10. ምን ያህል የጾታ ጓደኞች ኖረውሽ/ህ ያውቃሉ? 1 □     2    □     3  □
13.1 መልስሽ አዎ ከሆነ ኮንዶም ተጠቅመዋል? ሁልጊዜ □ አንዳንድ ጊዜ □ አላውቅም□
11. ከሴተኛ አዳሪ ጋር ግንኙት አድርገህ/ሽ/ ታውቃለህ/ሽ/?
አዎ□ አላውቅም□
11.1 መልስዎ አዎ ከሆነ ለምን ያህል ጊዜ?-----------------
11.2 ከሆነ ኮንዶም ተጠቅመዋል ? አዎ □ አልተጠቀምኩም □
12. ከዚህ ቀደም የአባላዛር በሽታታክመው ያውቃሉ? አዎ □ አላውቅም □
15.1 ከሆነ እድሜህ/ሽ/ ስንት ነበር?---------------
13. የውስጥ ሱሪ እንዲሁም የሸንት ቤትመታጠቢያወትን በጋራ ተጠቅመው ያውቃሉ?
አዎ □ አላውቅም □
14. የ ኤች አይቪምርመራ አድርገው ያውቃሉ ? አዎ□ አላውቅም□
አዎ ከሆነውጤትምን ነበር?
አለ □ የለም □ አላውቅም□
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Annex V . Laboratory (Culture) reporting Format
D
a
t
e
cod
e
Card
no
TV Candi
d
specie
s
Gram negative
diplococci
Growth
on TMT
Ox. Cat Super
oxidase
Sensiti
vity
BC
G G L M
Intra Extra S I R
Key: Y= Yes, N=No, Key: TV= T. vaginalis TE=tetracycline, CIP= ciprofloxacin, CRO=
ceftriaxone, CTX= cefotaxime, P= penicillin, FOX=cefoxitin, CLD= clindmycin, OX= oxidase,
CAT= catalyse, S=Sensitive, I=Intermediate, R=Resistance, Intra= Intracellular, Extra=
Extracellular, BC=Biochemical Tests
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